Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2–specific memory T cell responses
Despite the widespread use of SARS-CoV-2–specific monoclonal antibody (mAb) therapy for the treatment of acute COVID-19, the impact of this therapy on the development of SARS-CoV-2–specific T cell responses has been unknown, resulting in uncertainty as to whether anti–SARS-CoV-2 mAb administration m...
Main Authors: | Sydney I. Ramirez, Alba Grifoni, Daniela Weiskopf, Urvi M. Parikh, Amy Heaps, Farhoud Faraji, Scott F. Sieg, Justin Ritz, Carlee Moser, Joseph J. Eron, Judith S. Currier, Paul Klekotka, Alessandro Sette, David A. Wohl, Eric S. Daar, Michael D. Hughes, Kara W. Chew, Davey M. Smith, Shane Crotty, for the Accelerating COVID-19 Therapeutic Interventions and Vaccines–2/A5401 (ACTIV-2/A5401) Study Team |
---|---|
Format: | Article |
Language: | English |
Published: |
American Society for Clinical investigation
2022-12-01
|
Series: | JCI Insight |
Subjects: | |
Online Access: | https://doi.org/10.1172/jci.insight.163471 |
Similar Items
-
Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19
by: Kara W. Chew, et al.
Published: (2022-08-01) -
ACTIV-6: Operationalizing a decentralized, outpatient randomized platform trial to evaluate efficacy of repurposed medicines for COVID-19
by: The Accelerating Covid-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group
Published: (2023-01-01) -
Publisher Correction: Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19
by: Kara W. Chew, et al.
Published: (2023-01-01) -
Development of a Bamlanivimab Infusion Process in the Emergency Department for Outpatient COVID-19 Patients
by: Danny H. Pham, et al.
Published: (2021-12-01) -
The Therapeutic Monoclonal Antibody Bamlanivimab Does Not Enhance SARS-CoV-2 Infection by FcR-Mediated Mechanisms
by: Robert W. Cross, et al.
Published: (2023-11-01)